1. Home
  2. UTSI vs SNTI Comparison

UTSI vs SNTI Comparison

Compare UTSI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UTStarcom Holdings Corp.

UTSI

UTStarcom Holdings Corp.

HOLD

Current Price

$2.44

Market Cap

23.6M

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.80

Market Cap

24.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTSI
SNTI
Founded
1991
2016
Country
China
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
24.5M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
UTSI
SNTI
Price
$2.44
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.00
AVG Volume (30 Days)
1.6K
98.4K
Earning Date
08-29-2025
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$150.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.94
$0.79
52 Week High
$2.94
$5.10

Technical Indicators

Market Signals
Indicator
UTSI
SNTI
Relative Strength Index (RSI) 50.85 33.90
Support Level $2.34 N/A
Resistance Level $2.57 $1.02
Average True Range (ATR) 0.09 0.05
MACD 0.00 -0.01
Stochastic Oscillator 82.86 7.30

Price Performance

Historical Comparison
UTSI
SNTI

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: